Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Response Biomedical (V.RBM) -- Ignore unavailable to you. Want to Upgrade?

To: Starowl who wrote (420)	1/10/2002 3:49:22 PM
From: Dick Martin	Respond to of 655

RESPONSE BIOMEDICAL ON CBC NEWSWORLD - I don't have a television machine so i hope somebody can report back on the interview - Dick Vancouver, British Columbia, January 10, 2001. Response Biomedical Corp. (RBM: CDNX) developer of the RAMP* diagnostic system, advises that an interview with Bill Radvak, President and CEO of Response Biomedical, is scheduled to appear today on the Business News Report on CBC NewsWorld. Mr. Radvak discusses the impact U.S. FDA clearance of its proprietary RAMP System is expected to have on the Company. The interview is scheduled to be televised today at 3:30 and 9:30 pm Pacific Standard Time. The interview may also be on the 6 pm news on CBC television in the Western region. About Response Biomedical Corp. Response Biomedical develops quantitative, diagnostic tests for use with its proprietary RAMP Reader intended to be used for clinical, STAT-lab and point-of-care applications. The RAMP System is expected to reduce the cost of healthcare by allowing rapid and easy-to-use medical tests to be performed in hospitals, clinics, laboratories and physicians' offices worldwide. The Company's platform technology has the potential to be used with more than 250 medical and non-medical tests that are currently performed in laboratories including detection of biological materials used in bioterrorism. Response Biomedical's shares are listed on the Canadian Venture Exchange under the trading symbol "RBM". For further information, visit the Company's website at responsebio.com. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. The statements made in this investor advisory and the interview to which this advisory refers to, may contain certain forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ from the Company's expectations. Company Contact: John Gomez Manager, Corporate Communications Response Biomedical Corp. Tel (604) 681-4101 Fax (604) 412-9830 Email: jgomez@responsebio.com